Biodegradable stent英文文献资料.docVIP

J. Biomedical Science and Engineering, 2012, 5, 208-216 JBiSE /10.4236/jbise.2012.54028 Published Online April 2012 (http://www.SciRP.org/journal/jbise/) Biodegradable stent Doo Yeon Kwon , Jae Il Kim , Da Yeon Kim , Hwi Ju Kang , Bong Lee , Kang Woo Lee , 1* 1* 1 1 2 3 1# Moon Suk Kim 1 2 3 Department of Molecular Science and Technology, Ajou University, Suwon, Korea (South) Department of Polymer Engineering, Pukyong National University, Busan, Korea (South) Office of RD Program Management, Korea Evaluation Institute of Industrial Technology, Seoul, Korea (South) Email: moonskim@ajou.ac.kr # Received 11 January 2012; revised 31 January 2012; accepted 23 February 2012 ABSTRACT coronary artery to expand the coronary artery [4]. The insertion of BMS had lower restenosis occurrence rate than balloon expansion, and the stent played the role of supporting the blood vessel inner wall to prevent the contraction of the coronary artery reducing the restenosis rate to 20% - 30%. Stent insertion reduced the critical shortfall of balloon expansion which was the stricture of coronary artery with acute recoil, but mechanical blood vessel damage was caused in the expansion process and neointimal was formed to cause in stent restenosis [5,6]. In order to prevent in stent restenosis, many researches were conducted, and sirolimus originally developed as immunosuppressant and paclitaxel used as anticancer drug were reported to effectively suppress formation of neointimal [7,8]. The problem was, however, systemic injection of such drugs interfere with maintaining the local drug concentration in the stent, and is prone to se- rious side effects. In order to overcome such problems, the research to insert the drug on the s